Cytosorbents (NASDAQ:CTSO) Coverage Initiated by Analysts at StockNews.com

Stock analysts at StockNews.com started coverage on shares of Cytosorbents (NASDAQ:CTSO) in a report issued on Sunday. The brokerage set a “hold” rating on the medical research company’s stock.

A number of other analysts have also commented on CTSO. HC Wainwright reaffirmed a “neutral” rating and set a $1.00 price objective on shares of Cytosorbents in a research note on Wednesday, August 14th. EF Hutton Acquisition Co. I raised shares of Cytosorbents to a “strong-buy” rating in a research note on Monday, July 29th.

Cytosorbents Stock Up 14.8 %

CTSO stock opened at $1.24 on Friday. The company’s 50-day moving average price is $1.05 and its 200 day moving average price is $0.94. Cytosorbents has a 52 week low of $0.70 and a 52 week high of $2.15. The company has a market cap of $67.34 million, a P/E ratio of -2.10 and a beta of 0.50. The company has a current ratio of 2.12, a quick ratio of 1.71 and a debt-to-equity ratio of 0.82.

Cytosorbents (NASDAQ:CTSO) last announced its earnings results on Tuesday, August 13th. The medical research company reported ($0.08) EPS for the quarter, topping the consensus estimate of ($0.09) by $0.01. Cytosorbents had a negative net margin of 68.70% and a negative return on equity of 131.84%. The company had revenue of $9.89 million during the quarter, compared to analysts’ expectations of $9.73 million. During the same period last year, the company posted ($0.14) earnings per share. On average, research analysts expect that Cytosorbents will post -0.32 earnings per share for the current fiscal year.

Institutional Trading of Cytosorbents

A number of institutional investors have recently bought and sold shares of CTSO. Key Client Fiduciary Advisors LLC increased its holdings in Cytosorbents by 188.0% in the 1st quarter. Key Client Fiduciary Advisors LLC now owns 34,557 shares of the medical research company’s stock worth $33,000 after acquiring an additional 22,557 shares in the last quarter. CM Management LLC lifted its holdings in Cytosorbents by 98.8% in the first quarter. CM Management LLC now owns 825,000 shares of the medical research company’s stock valued at $784,000 after acquiring an additional 410,000 shares during the period. Sargent Investment Group LLC increased its position in shares of Cytosorbents by 4.9% in the second quarter. Sargent Investment Group LLC now owns 1,433,500 shares of the medical research company’s stock valued at $1,008,000 after buying an additional 67,181 shares in the last quarter. Neuberger Berman Group LLC grew its holdings in Cytosorbents by 19.9% in the 4th quarter. Neuberger Berman Group LLC now owns 1,801,799 shares of the medical research company’s stock valued at $1,997,000 after buying an additional 299,103 shares during the period. Finally, Avenir Corp lifted its stake in shares of Cytosorbents by 12.3% in the 4th quarter. Avenir Corp now owns 3,051,402 shares of the medical research company’s stock valued at $3,387,000 after purchasing an additional 334,005 shares in the last quarter. 32.87% of the stock is currently owned by institutional investors and hedge funds.

About Cytosorbents

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals.